This study demonstrated an association between the increased risk of biopsy-confirmed NAFLD and PNPLA3 as well as TM6SF2 variants and a trend towards a lower NAFLD risk in carriers of the HSD17B13 polymorphism. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatotic liver disease.